GLOBAL FUND WELCOMES RENEWED COMMITMENT FROM GSK AND ViiV HEALTHCARE TO EXPAND COMMUNITY-LED HEALTH SOLUTIONS WITH £6 MILLION JOINT PLEDGE AHEAD OF 8TH REPLENISHMENT

Deborah Waterhouse, CEO, ViiV Healthcare and President, Global Health GSK said: “We are proud to deepen our partnership with the Global Fund through this catalytic investment, which will help accelerate community-led responses to high burden infectious diseases such as HIV, tuberculosis, and malaria. We believe that sustainable health impact begins with empowering communities and the local organisations that know them best. By supporting programmes that are led by countries, community-owned and community-driven, we’re helping to build stronger, more resilient health systems where they’re needed most.”

Hon. Ronald Lamola, Minister of International Relations and Cooperation of the Republic of South Africa, said, “South Africa is proud to co-host the Global Fund’s 8th Replenishment, and we welcome the renewed commitment from GSK and ViiV Healthcare to innovation and equity in global health. Partnerships like these — between governments, the private sector, and communities — are essential to sustain progress against HIV and malaria. As we look toward the pledging summit, South Africa calls on all partners to match this spirit of solidarity and ambition, so that together we can build a healthier, more resilient world for all.”

GSK and ViiV Healthcare have long led innovation in the fight against HIV, malaria and TB, developing solutions that have helped to reduce the burden on communities most affected by highly prevalent infectious diseases. Their advances include a portfolio of medicines and vaccines which are used in the global setting for the treatment and prevention of diseases such as malaria and HIV, and a pipeline which includes research programmes for a next generation malaria vaccine and HIV medicines, and a vaccine candidate for TB – being developed in partnership with Gates MRI, Gates Foundation and Wellcome, all aimed at helping to accelerate the progress toward ending these diseases.

“The Global Fund continues to demonstrate how partnership can drive innovation and deliver impact where it’s needed most,” said Joe Cerrell, Managing Director, Europe, the Middle East and East Asia of the Gates Foundation. “As part of our ongoing commitment, we’re announcing up to $100 million in matching funds to unlock greater private and philanthropic investment. We’re proud that the first contribution - £6 million from GSK and ViiV Healthcare - will activate this matching support. This collaboration underscores the Global Fund’s unique ability to turn bold ideas into real-world results, and we hope it will inspire others to join us in accelerating progress against HIV, TB, and malaria.”

Through this new investment with the Global Fund, GSK and ViiV Healthcare are continuing to go beyond scientific innovation, to help improve health outcomes for communities in lower income countries. The funding will support locally led partners and programmes accelerating progress in some of the world’s most affected regions. This commitment reinforces the vital role of grassroots leadership in shaping sustainable health solutions and comes at a pivotal time in the global health response, when catalytic funding for community-owned and community-led change is more important than ever.

“This commitment from GSK and ViiV Healthcare sends a powerful message - when public and private actors unite around a shared vision, we can drive real, lasting change,” said Peter Sands, Executive Director of the Global Fund. “We deeply appreciate their generosity and leadership at this critical moment. The innovation of the private sector is central to our partnerships progress, and the renewed pledge will continue our work to ensure those most impacted by infectious diseases, including women and girls, can access the best care when they need it.”

Catalytic funds, such as the one supported through this new pledge, are designed to tackle high-impact, high-priority initiatives that complement country allocations - driving innovation and accelerating progress in areas where it is most needed, for underserved communities.

Early and ambitious private sector commitments like this one are instrumental in building momentum, strengthening confidence in collective action, and inspiring others to contribute to the global effort to end HIV, TB, and malaria.

About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.